Article Text
PDFLetter
The influence of the pharmaceutical industry on the off-label use of its medicines
Statistics from Altmetric.com
Last year I described in this journal1 an unacceptable influence of a pharmaceutical company on the off-label use of one of its products. Now I would like to report on an acceptable and even praiseworthy initiative of a pharmaceutical manufacturer in monitoring the use of its drug. The devastating action of thalidomide on the human embryo caused its withdrawal from the market in …
Read the full text or download the PDF:
Other content recommended for you
- Unlicensed and off label drug use in neonates
- Emerging role of thalidomide in the treatment of gastrointestinal bleeding
- Intravitreal thalidomide reduces experimental preretinal neovascularisation without induction of retinal toxicity
- Frances Kathleen Oldham Kelsey
- Absence of significant adverse events following thalidomide administration in bitches diagnosed with mammary gland carcinomas
- Survey of unlicensed and off label drug use in paediatric wards in European countries
- Seroxat and the suppression of clinical trial data: regulatory failure and the uses of legal ambiguity
- Thalidomide and its derivatives: emerging from the wilderness
- Licensing of medicines
- Hair repigmentation associated with thalidomide use for the treatment of multiple myeloma